Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at der var påvist tilstrækkelig virkning af pioglitazon og glimepirid ved behandling af type 2- diabetes, og at Tandemact forenkler behandlingen og gør det lettere for patienterne at følge behandlingen, når der er behov for en kombination af de to aktive indholdsstoffer.
The Committee for Medicinal Products for Human Use (CHMP) concluded that the effectiveness of pioglitazone and glimepiride in type 2 diabetes had been shown, and that Tandemact simplifies treatment and improves the ability of patients to stick to their treatment when a combination of the two active substances is needed.